Metacrine to Present at 2021 RBC Global Healthcare Conference
May 11 2021 - 8:05AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with liver
and gastrointestinal diseases, today announced that Preston
Klassen, M.D., MHS, president and chief executive officer, will
present virtually at the 2021 RBC Global Healthcare Conference at
5:25 p.m. ET on Tuesday, May 18, 2021.
A live webcast of the presentation will be available at
https://investors.metacrine.com/events-and-presentations. A replay
of the webcast will be archived for 30 days following the
conference.
About Metacrine
Metacrine, Inc. is a clinical-stage
biopharmaceutical company building a pipeline of differentiated
therapies to treat liver and gastrointestinal diseases. Metacrine
has developed a proprietary farnesoid X receptor (FXR) platform
utilizing a unique chemical scaffold, which has demonstrated an
improved therapeutic profile in clinical trials. The Company’s two
product candidates, MET409 and MET642, are currently being
investigated in clinical trials as potential new treatments for
NASH. MET409 has completed a 12-week monotherapy trial in patients
with NASH and is being evaluated in a 12-week combination trial
with empagliflozin in patients with both NASH and type 2 diabetes.
MET642 has completed a 14-day Phase 1 trial in healthy volunteers
and is being evaluated in a 16-week monotherapy trial in patients
with NASH. To learn more, visit www.metacrine.com.
Investor & Media ContactSteve
KunszaboMetacrine, Inc.+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Sep 2023 to Sep 2024